Can Platelet-to-Lymphocyte Ratio (PLR) and Neutrophil-to-Lymphocyte Ratio (NLR) Help Predict Outcomes of Patients With Recurrent Glioblastoma?
In Vivo2024Vol. 38(5), pp. 2341–2348
Citations Over Time
Abstract
In addition to other characteristics, PLR at the time of recurrence was identified as an independent predictor of OS in patients with recurrent glioblastoma. PLR may be useful when designing personalized treatment approaches or clinical trials.
Related Papers
- → The evaluation of pretreatment neutrophil–lymphocyte ratio and derived neutrophil–lymphocyte ratio in patients with laryngeal neoplasms(2018)33 cited
- → Prognostic value of preoperative neutrophil-to-lymphocyte ratio in Crohn’s disease(2018)18 cited
- → Prediction of outcomes after chemoradiotherapy for cervical cancer by neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio(2024)5 cited
- → Neutrophil to Hemoglobin Lymphocyte Ratio (NHLR) as a Novel Biomarker is Superior to Neutrophil Lymphocyte Ratio (NLR) and Platelet Lymphocyte Ratio (PLR) as Predictors of Advanced Colorectal Cancer(2024)1 cited
- → WCN23-0288 ROLE OF NEUTROPHIL LYMPHOCYTE RATIO(NLR) AND PLATELET LYMPHOCYTE RATIO(PLR ) AS MARKERS OF DISEASE ACTIVITY IN SLE PATIENTS WITH OR WITHOUT RENAL INVOLVEMENT(2023)